Favorable response to tyrosine kinase (TK) inhibitors targeting the epidermal growth factor receptor (EGFR), in cases of NSCLC in which mutations are present in the EGFR gene, illustrate the importance of the identification of molecular biomarkers, and several such oncogenic alterations has been reported to date [1–3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.